Viewing Study NCT04876651


Ignite Creation Date: 2025-12-24 @ 11:50 PM
Ignite Modification Date: 2025-12-25 @ 9:44 PM
Study NCT ID: NCT04876651
Status: RECRUITING
Last Update Posted: 2024-05-31
First Post: 2021-05-03
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module